|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies |
|||||||||||
|
|
|||||||||||
|
14 April 2023
AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 15 – 18 April 2023, reinforcing its ambition to provide long-lasting immunity for millions of people globally. The company will present 15 abstracts, including four oral presentations, at the event. |
|||||||||||
|